MAPT and Alzheimer disease: Abnormal accumulation of tau is seen across various central nervous system disorders such as AD, Pick’s disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease; thus, targeting tau offers the possibility not only of treating AD itself but also of treating many other tauopathies associated with Aβ.